Immune Checkpoint Inhibitors in Cancer Therapy: Review of Orofacial Adverse Events and Role of the Oral Healthcare Provider.

Alessandro Villa; Additional authors and institutional affiliations

doi:10.3389/froh.2022.968157

Immune Checkpoint Inhibitors in Cancer Therapy: Review of Orofacial Adverse Events and Role of the Oral Healthcare Provider.

Alessandro Villa, Additional authors and institutional affiliations

Miami Cancer Institute

Research output: Contribution to journal › Article › peer-review

Abstract

Immune checkpoint inhibitors (ICIs) are a revolutionary class of antineoplastic therapy that restore anti-tumor immunity. Consequences of this enhanced immune response include a multitude of immune related adverse events (irAEs) that can affect any body system, including the mouth. Orofacial irAEs reproduce features of numerous immune-mediated conditions, including oral lichen planus, mucous membrane pemphigoid, and Sjögren syndrome, among others. The aim of this review is to summarize known orofacial irAEs and to familiarize oral healthcare providers with how to identify and manage these toxicities as part of the care team for patients treated with ICIs.

Original language	American English
Journal	Frontiers in Oral Health
Volume	3
DOIs	https://doi.org/10.3389/froh.2022.968157
State	Published - Aug 11 2022

Keywords

Cancer Therapy
Immune Checkpoint Inhibitors
Oral Healtcare
Orofacial
Review

Disciplines

Medicine and Health Sciences

Access to Document

10.3389/froh.2022.968157License: Unspecified

Cite this

@article{6019835bed8040d1a25162207fcd92da,

title = "Immune Checkpoint Inhibitors in Cancer Therapy: Review of Orofacial Adverse Events and Role of the Oral Healthcare Provider.",

abstract = " Immune checkpoint inhibitors (ICIs) are a revolutionary class of antineoplastic therapy that restore anti-tumor immunity. Consequences of this enhanced immune response include a multitude of immune related adverse events (irAEs) that can affect any body system, including the mouth. Orofacial irAEs reproduce features of numerous immune-mediated conditions, including oral lichen planus, mucous membrane pemphigoid, and Sj{\"o}gren syndrome, among others. The aim of this review is to summarize known orofacial irAEs and to familiarize oral healthcare providers with how to identify and manage these toxicities as part of the care team for patients treated with ICIs. ",

keywords = "Cancer Therapy, Immune Checkpoint Inhibitors, Oral Healtcare, Orofacial, Review",

author = "Alessandro Villa and {and institutional affiliations}, {Additional authors}",

note = "Immune checkpoint inhibitors (ICIs) are a revolutionary class of antineoplastic therapy that restore anti-tumor immunity. Consequences of this enhanced immune response include a multitude of immune related adverse events (irAEs) that can affect any body system, including the mouth. Orofacial irAEs r ...",

year = "2022",

month = aug,

day = "11",

doi = "10.3389/froh.2022.968157",

language = "American English",

volume = "3",

journal = "Frontiers in Oral Health",

}

TY - JOUR

T1 - Immune Checkpoint Inhibitors in Cancer Therapy: Review of Orofacial Adverse Events and Role of the Oral Healthcare Provider.

AU - Villa, Alessandro

AU - and institutional affiliations, Additional authors

N1 - Immune checkpoint inhibitors (ICIs) are a revolutionary class of antineoplastic therapy that restore anti-tumor immunity. Consequences of this enhanced immune response include a multitude of immune related adverse events (irAEs) that can affect any body system, including the mouth. Orofacial irAEs r ...

PY - 2022/8/11

Y1 - 2022/8/11

N2 - Immune checkpoint inhibitors (ICIs) are a revolutionary class of antineoplastic therapy that restore anti-tumor immunity. Consequences of this enhanced immune response include a multitude of immune related adverse events (irAEs) that can affect any body system, including the mouth. Orofacial irAEs reproduce features of numerous immune-mediated conditions, including oral lichen planus, mucous membrane pemphigoid, and Sjögren syndrome, among others. The aim of this review is to summarize known orofacial irAEs and to familiarize oral healthcare providers with how to identify and manage these toxicities as part of the care team for patients treated with ICIs.

AB - Immune checkpoint inhibitors (ICIs) are a revolutionary class of antineoplastic therapy that restore anti-tumor immunity. Consequences of this enhanced immune response include a multitude of immune related adverse events (irAEs) that can affect any body system, including the mouth. Orofacial irAEs reproduce features of numerous immune-mediated conditions, including oral lichen planus, mucous membrane pemphigoid, and Sjögren syndrome, among others. The aim of this review is to summarize known orofacial irAEs and to familiarize oral healthcare providers with how to identify and manage these toxicities as part of the care team for patients treated with ICIs.

KW - Cancer Therapy

KW - Immune Checkpoint Inhibitors

KW - Oral Healtcare

KW - Orofacial

KW - Review

UR - https://pubmed.ncbi.nlm.nih.gov/36060116/

U2 - 10.3389/froh.2022.968157

DO - 10.3389/froh.2022.968157

M3 - Article

VL - 3

JO - Frontiers in Oral Health

JF - Frontiers in Oral Health

ER -

Immune Checkpoint Inhibitors in Cancer Therapy: Review of Orofacial Adverse Events and Role of the Oral Healthcare Provider.

Abstract

Keywords

Disciplines

Access to Document

Other files and links

Cite this